Keros Therapeutics Inc. (KROS)
Keros Therapeutics Statistics
Share Statistics
Keros Therapeutics has 40.51M shares outstanding. The number of shares has increased by 12.57% in one year.
| Shares Outstanding | 40.51M |
| Shares Change (YoY) | 12.57% |
| Shares Change (QoQ) | 7.96% |
| Owned by Institutions (%) | 96.73% |
| Shares Floating | 32.87M |
| Failed to Deliver (FTD) Shares | 988 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 4.02M, so 9.92% of the outstanding shares have been sold short.
| Short Interest | 4.02M |
| Short % of Shares Out | 9.92% |
| Short % of Float | 12.23% |
| Short Ratio (days to cover) | 2.14 |
Valuation Ratios
The PE ratio is -3.16 and the forward PE ratio is -3.11. Keros Therapeutics's PEG ratio is 0.82.
| PE Ratio | -3.16 |
| Forward PE | -3.11 |
| PS Ratio | 166.94 |
| Forward PS | 3.2 |
| PB Ratio | 1.04 |
| P/FCF Ratio | -3.64 |
| PEG Ratio | 0.82 |
Enterprise Valuation
Keros Therapeutics Inc. has an Enterprise Value (EV) of 854.11M.
| EV / Earnings | -4.56 |
| EV / Sales | 240.6 |
| EV / EBITDA | -4.05 |
| EV / EBIT | -4.05 |
| EV / FCF | -5.25 |
Financial Position
The company has a current ratio of 21.45, with a Debt / Equity ratio of 0.03.
| Current Ratio | 21.45 |
| Quick Ratio | 21.45 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3.19 |
| Cash Flow / Debt | -8.53 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on capital (ROIC) is -35.65%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -35.65% |
| Revenue Per Employee | 21.01K |
| Profits Per Employee | -1.11M |
| Employee Count | 169 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -300K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -83.89% in the last 52 weeks. The beta is 1.4, so Keros Therapeutics's price volatility has been higher than the market average.
| Beta | 1.4 |
| 52-Week Price Change | -83.89% |
| 50-Day Moving Average | 12.92 |
| 200-Day Moving Average | 42.76 |
| Relative Strength Index (RSI) | 35.85 |
| Average Volume (20 Days) | 1.67M |
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.
| Revenue | 3.55M |
| Gross Profit | 3.55M |
| Operating Income | -210.83M |
| Net Income | -187.35M |
| EBITDA | -210.83M |
| EBIT | -210.83M |
| Earnings Per Share (EPS) | -5 |
Balance Sheet
The company has 559.93M in cash and 18.86M in debt, giving a net cash position of 541.07M.
| Cash & Cash Equivalents | 559.93M |
| Total Debt | 18.86M |
| Net Cash | 541.07M |
| Retained Earnings | -568.78M |
| Total Assets | 579.27M |
| Working Capital | 523.04M |
Cash Flow
In the last 12 months, operating cash flow was -160.87M and capital expenditures -1.93M, giving a free cash flow of -162.8M.
| Operating Cash Flow | -160.87M |
| Capital Expenditures | -1.93M |
| Free Cash Flow | -162.8M |
| FCF Per Share | -4.35 |
Margins
Gross margin is 100%, with operating and profit margins of -5.94K% and -5.28K%.
| Gross Margin | 100% |
| Operating Margin | -5.94K% |
| Pretax Margin | -5.27K% |
| Profit Margin | -5.28K% |
| EBITDA Margin | -5.94K% |
| EBIT Margin | -5.94K% |
| FCF Margin | -4.59K% |
Dividends & Yields
KROS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -45.09% |
| FCF Yield | -36.26% |
Analyst Forecast
The average price target for KROS is $26, which is 134.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $26 |
| Price Target Difference | 134.4% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 4.42 |
| Piotroski F-Score | 5 |